



19

Europäisches Patentamt

European Patent Office

Office européen des brevets



⑪ Publication number:

0 684 043 A1

12

EUROPEAN PATENT APPLICATION

② Application number: 95106146.4

⑤1 Int. Cl. 6. A61K 31/665

② Date of filing: 25.04.95

③ Priority: 28.04.94 JP 90418/94

(43) Date of publication of application:
29.11.95 Bulletin 95/48

84) Designated Contracting States:

Designated Contracting States:
**AT BE CH DE DK ES FR GB GR IE IT LI LU MC
NL PT SE**


(71) Applicant: **Senju Pharmaceutical Co., Ltd.**
5-8, Hiranomachi 2-chome,
Chuo-Ku
Osaka-shi,
Osaka 541 (JP)

(72) Inventor: **Tsubota, Kazuo**
5-26-7 Nishifuna
Funabashi-shi,
Chiba 273 (JP)

74) Representative: von Kreisler, Alek,
Dipl.-Chem. et al
Patentanwälte,
von Kreisler-Selting-Werner,
Bahnhofsvorplatz 1 (Deichmannhaus)
D-50667 Köln (DE)

(54) Therapeutic composition for corneal impairment containing a phosphonic acid diester compound.

57) This invention provides a therapeutic composition for corneal impairment which comprises a phosphoric acid ester compound of the following formula or a pharmacologically acceptable salt thereof.



wherein R₁ and R₂ are the same or different and each represents a hydrogen atom or a methyl group.

The therapeutic composition of this invention is useful for the treatment of electricity-related ophthalmia, snow-related ophthalmia, corneal lesions caused by contact lens wearing, and corneal impairment associated with hypolacrilia.

EP 0684 043 A1

BACKGROUND OF THE INVENTION

1. Field of the Invention

5 This invention relates to a useful therapeutic composition for corneal impairment. More particularly, this invention relates to a pharmaceutical composition useful for the therapy of corneal impairment which comprises an ascorbyl tocopheryl phosphate compound or a pharmacologically acceptable salt thereof.

2. Description of the Prior Art

10

The cornea consists of the ectoblastic epithelium, mesoblastic outer boundary layer (Bowman's membrane), substantia propria, inner boundary layer (Descemet's membrane), and endothelium. Being situated in the outermost part of the eyeball, the cornea is susceptible to various influences of the external environment so that it may sustain various injuries. As typical lesions of the cornea, ultraviolet light-induced keratitis (i.e. electricity-related ophthalmia and snow-related ophthalmia etc.) may be mentioned. Another 15 corneal disease is dry eye (hypolacrimia, xerophthalmia, keratoconjunctivitis sicca) which develop as the corneal and conjunctival epithelia are injured in a deficiency of lacrimal secretion due to various causes such as many hours of eye-straining work, a dry environment, or oxidative substances (oxidants) in the atmosphere. The lacrimal secretions contain free-radical scavengers such as SOD (superoxide dismutase) 20 in high concentrations and the injurious effect of these scavengers is thought to be amplified in dry eye because of the paucity of lacrimal secretion. Another type of corneal impairment is one caused by a sudden change in oxygen partial pressure due to contact lens wearing. It is suspected that in all of these types of corneal injuries, the free radicals generated by various causes exemplified above are a major contributory factor.

25

As therapeutic drugs for snow ophthalmia and other corneal diseases caused by ultraviolet radiation, among the above-mentioned diseases, either steroid or non-steroidal antiinflammatory drugs have heretofore been indicated and used. Among them, steroid antiinflammatory drugs are relatively more potent in antiinflammatory action but are disadvantageous in that their usage may entail serious adverse reactions. Therefore, these drugs must be administered only cautiously under close observation of the clinical course.

30

On the other hand, nonsteroidal antiinflammatory drugs have the disadvantage of being less potent than said steroid drugs. Meanwhile, artificial tears are generally indicated in the treatment of hypolacrimia but this therapy does nothing but making up for a decrease in lacrimal secretion only for a brief time and cannot inhibit the above-mentioned free radicals, with the result that its therapeutic efficacy can hardly be considered to be sufficient.

35

The state of the art is that, for the above-mentioned diseases of the cornea, there is available no satisfactory drugs in terms of efficacy and side effect. Therefore, a need has been felt for a drug which would be more effective and useful for the treatment of these corneal diseases.

40

Under the circumstances summarized above, the inventor of this invention explored into the pharmacological actions of ascorbyl tocopheryl phosphate compounds and found that these compounds effectively inhibit the corneal impairment due to free radicals generated due to ultraviolet radiation or contact lens wearing and are useful for the treatment of electricity-related ophthalmia, snow-related ophthalmia, corneal lesions caused by contact lens wearing, and corneal impairment associated with hypolacrimia. This invention has been developed on the basis of the above finding.


45 **SUMMARY OF THE INVENTION**

This invention, therefore, is concerned with:

(1) A therapeutic composition for corneal impairment which comprises a phosphoric diester compound of the following formula or a pharmacologically acceptable salt thereof,

50

55



wherein R₁ and R₂ are the same or different and each represents a hydrogen atom or a methyl group;

- (2) the therapeutic composition for corneal impairment as defined under (1) wherein the corneal impairment is a lesion associated with ultraviolet radiation;
- (3) the therapeutic composition for corneal impairment as defined under (1) or (2) wherein the corneal impairment is electricity-related ophthalmia or snow-related ophthalmia;
- (4) the therapeutic composition for corneal impairment as defined under (1) wherein the corneal impairment is a lesion associated with hypolacrimia; and
- (5) the therapeutic composition for corneal impairment as defined under (1) wherein the corneal impairment is a lesion associated with contact lens wearing.

25 **BRIEF DESCRIPTION OF THE DRAWING**

Fig. 1 is a graph showing the degrees of UV-induced corneal lesion in the control group and the present compound treatment group. The abscissa represents time and the ordinate represents the fluorescence intensity of fluorescein sodium penetrating into the rabbit cornea.

30 The symbols used in Fig. 1 represent:

- : the present compound treatment group
- + : the control group

DETAILED DESCRIPTION OF THE INVENTION

35

The present compound for use in the therapeutic composition for corneal impairment according to this invention can be synthesized by *inter alia* the processes in Japanese Patent Publication H-2-44478 and Japanese Patent Application Kokai S-62-205091, or any process analogous therewith.

40 For the present compound as an active ingredient of the therapeutic composition for corneal impairment, a variety of uses such as an anticataract agent, a prophylactic and therapeutic agent for climacteric disturbance, a skin care cosmetic ingredient (Japanese Patent Publication H-2-44478), an antiinflammatory agent (Japanese Patent Publication H-1-27044), an antilulcer agent (Japanese Patent Application Kokai S-63-270626), a prophylactic and therapeutic agent for ischemic organic impairment (Japanese Patent Application Kokai H-2-111722) and a Maillard reaction inhibitor (Japanese Patent Application Kokai H-3-161444) are 45 already known.

The present compound for use in the therapeutic composition for corneal impairment according to this invention may be a free compound or a pharmacologically acceptable salt. The pharmacologically acceptable salt typically includes salts with alkali metals such as sodium, potassium, etc. and salts with alkaline earth metals such as calcium, magnesium, and so on. However, any other salt can be likewise be 50 employed only if it is pharmacologically acceptable.

The therapeutic composition for corneal impairment according to this invention may contain one or more species of the present compound according to the intended use and need.

55 The compound for use as an active ingredient in the therapeutic composition for corneal impairment according to this invention is a very safe substance with an extremely low toxic potential and, as such, can be used with advantage for the purposes of this invention.

[e.g. the LD₅₀ values of L-ascorbyl DL- α -tocopheryl phosphate potassium (hereinafter referred to briefly as EPC-K) \geq 5 g/kg p.o. (rats) and \geq 100 mg/kg i.v. (rats)].

The corneal lesion that can be treated with the therapeutic composition for corneal impairment according to this invention includes electricity-related ophthalmia, snow-related ophthalmia, corneal lesions caused by contact lens wearing, and corneal impairment associated with hypolacrilia.

5 The therapeutic composition for corneal impairment of this invention can be administered either orally (e.g. tablets etc.) or otherwise (e.g. ophthalmic solutions, ophthalmic ointments, injections, etc.) for the treatment of the above-mentioned corneal impairment. The dosage form in which the therapeutic composition of this invention can be provided includes ophthalmic solutions, ophthalmic ointments, tablets, granules, powders, capsules, injections and so on. These dosage forms can be manufactured by the established pharmaceutical procedures. In such dosage forms, a variety of additives such as excipients, binders, 10 disintegrators, dispersants, reabsorption promoters, buffers, surfactants, solubilizers, preservatives, emulsifiers, isotonizing agents, stabilizers and pH control agents can be incorporated in appropriate amounts.

15 In application of the present compound as a therapeutic drug for corneal impairment, its dosage depends on the species of compound, the type of disease to be treated, the patient's age and body weight, clinical manifestations that must be controlled, and the dosage form but recommended daily injection dose for an adult patient is about 1 mg-100 mg. In the case of an oral preparation, about 10 mg-1000 mg per dose can be administered a few times a day to the average adult. In the case of an ophthalmic solution, a few drops of a solution containing about 0.01-5% (w/v), preferably about 0.05-2% (w/v), of the present compound can be instilled into the eye several times daily for the average adult. In the case of an ophthalmic ointment, a formulation containing about 0.01-5% (w/w), preferably about 0.05-2% (w/w), of the 20 present compound can be applied several times daily for the average adult.

25 Unless contrary to the spirit and object of this invention, the pharmaceutical composition of this invention may further contain other therapeutic drugs for corneal impairment and/or other kinds of medicinal substances.

25 EXAMPLES

The following examples and formulation examples are intended to describe this invention in further detail.

30 Example 1 Inhibitory effect of the present compound on UV-induced corneal lesions in rabbits

The inhibitory effect of the present compound on UV-induced corneal lesions in rabbits was evaluated.

Test substance: L-Ascorbyl DL- α -tocopheryl phosphate potassium (abbreviation: EPC-K).

Method: White rabbits were used; 4 animals assigned to the present compound treatment group and 3 assigned to a control group (the nictitating membrane was excised beforehand).

For UV irradiation, Hoya-Schott's HLS200U (dominant wavelength 365 nm) equipped with a 200 W mercury-xenon lamp as the light source was used. Ushio Electric's Unimeter UIT-101 was used for the determination of luminous energy.

One eye of each rabbit was kept open with an eye speculum and set at a distance of 43 cm from the 40 light source so that the irradiation energy would be 0.024 J/cm². The eye was irradiated with ultraviolet light under the conditions of 0.2 mW/cm² and 2 minutes. The fellow eye was protected with an eye patch.

After UV irradiation, the vehicle (2.6% concentrated glycerin solution) was instilled in the eyes of rabbits in the control group 3 times daily and 0.1% EPC-K (dissolved in 2.6% concentrated glycerin solution) was instilled as often into the eyes of rabbits in the present compound treatment group.

45 The degree of rabbit corneal lesion was evaluated by the following method¹⁾. Using fluorescein as a tracer, the fluorescence intensity of the tracer dye penetrating into the cornea within a predetermined region was measured for a quantitative assessment of the barrier function of the corneal epithelium (The corneal epithelium has a barrier function²⁾ to restrict penetration of any substance into the deep layer of the cornea and when an erosion or other injury occurs in the corneal epithelium, this barrier function is compromised 50 so that the penetration of the substance into the depth of the cornea is increased). Thus, at 0, 0.5, 6, 12, 24, 48 and 72 hours after UV irradiation, fluorescein sodium was instilled into the eye and the fluorescence

55 1) Norihiko Yokoi et al.: Quantitative evaluation of corneal epithelial barrier function with a new fluorophotometer, Journal of the Eye, 10(8); 1357-1363, 1993

2) Klyce SD and Crosson CE: Transport processes across the rabbit corneal epithelium, a review. Curr Eye Res 4;427-432, 1985.

intensity of the fluorescein sodium that had penetrated into the cornea was measured with a Kowa anterior fluorophotometer.

Results: The results are shown in Table 1.

5

Table 1

10

Inhibitory effect of the present compound on UV-induced corneal lesion							
group	Time after irradiation (in hours)						
	0	0.5	6	12	24	48	72
Control group	457	791	899	3813	3860	870	655
Present compound treatment group	259	447	695	1038	875	343	311

15

Each figure in the table denotes the intensity of fluorescence.

Fig. 1 is a diagrammatic version of Table 1. It will be apparent from Table 1 and Fig. 1 that the drug of this invention effectively inhibits UV-induced corneal lesion.

20 **Formulation Example 1** Tablets for oral administration

25

EPC-K	100 mg
Lactose	75 mg
Starch	20 mg
Polyethylene glycol 6000	5 mg

30

The above components per tablet are mixed in the routine manner to provide tablets. Where necessary, the tablets may be sugar-coated.

35 **Formulation Example 2** Injection

40

EPC-K	200 mg
Mannitol	5.0 g
1N-Sodium hydroxide	q.s.
Distilled water	to make 100 ml
	pH 6.5

45

The above components are mixed and filtered through a membrane filter in the routine manner. The filtrate is aseptically filled in glass vials, 5 ml per vial, followed by sealing by fusion to provide an injectable preparation.

50

Formulation Example 3 Ophthalmic solution

55

EPC-K	0.5 g
Boric acid	1.8 g
Benzalkonium chloride	0.005 g
1N-Sodium hydroxide	q.s.
Sterilized pure water	to make 100 ml
	pH 7.3

The above components are mixed in the routine manner to provide an ophthalmic solution.

The pharmaceutical composition of this invention is of use as a therapeutic drug for corneal impairment such as electricity-related ophthalmia, snow-related ophthalmia, corneal lesions due to contact lens wearing and corneal impairment associated with hypolacrimia.


5 **Claims**

1. A therapeutic composition for corneal impairment which comprises a phosphoric diester compound of the following formula or a pharmacologically acceptable salt thereof,

10

15

20



wherein R₁ and R₂ are the same or different and each represents a hydrogen atom or a methyl group.

25

2. The therapeutic composition for corneal impairment as claimed in claim 1 wherein the corneal impairment is a lesion associated with ultraviolet radiation.

3. The therapeutic composition for corneal impairment as claimed in claim 1 or 2 wherein the corneal impairment is electricity-related ophthalmia or snow-related ophthalmia.

4. The therapeutic composition for corneal impairment as claimed in claim 1 wherein the corneal impairment is a lesion associated with hypolacrimia.

30 5. The therapeutic composition for corneal impairment as claimed in claim 1 wherein the corneal impairment is a lesion associated with contact lens wearing.

40

45

50

55




Fig.1



European Patent
Office

EUROPEAN SEARCH REPORT

Application Number
EP 95 10 6146

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claims	CLASSIFICATION OF THE APPLICATION (Int.Cl.)
P, X	INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, vol. 36, no. 4, 15 March 1995 page S696 M. SHIMOURA ET AL. 'THE ROLE OF OXIDATIVE STRESS IN ULTRAVIOLET INDUCED CORNEAL EPITHELIAL INJURY' * the whole document * ---	1-5	A61K31/665
P, X	EP-A-0 616 809 (SENJU PHARMACEUTICAL CO.) 28 September 1994 * the whole document * ---	1-5	
X	DATABASE WPI Week 9201 Derwent Publications Ltd., London, GB; AN 92-002618 & JP-A-03 255 027 (SENJU PHARM) , 13 November 1991 * abstract * ---	1-5	
D, X	EP-A-0 430 045 (SENJU PHARMACEUTICAL CO.) 5 June 1991 * abstract; claims; examples * ---	1-5	TECHNICAL FIELDS SEARCHED (Int.Cl.) A61K
D, X	EP-A-0 236 120 (SENJU SEIYAKU) 9 September 1987 * abstract; claims; examples * ---	1-5	
D, X	EP-A-0 127 471 (SENJU SEIYAKU) 5 December 1984 * abstract; claims; examples * ---	1-5 -/-	
The present search report has been drawn up for all claims			
Place of search	Date of completion of the search	Examiner	
THE HAGUE	25 July 1995	Hoff, P	
CATEGORY OF CITED DOCUMENTS			
X : particularly relevant if taken alone	T : theory or principle underlying the invention		
Y : particularly relevant if combined with another document of the same category	E : earlier patent document, but published on, or after the filing date		
A : technological background	D : document cited in the application		
O : non-written disclosure	L : document cited for other reasons		
P : intermediate document	A : member of the same patent family, corresponding document		



European Patent
Office

EUROPEAN SEARCH REPORT

Application Number
EP 95 10 6146

DOCUMENTS CONSIDERED TO BE RELEVANT			CLASSIFICATION OF THE APPLICATION (Int.Cl.6)
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	
A	<p>STN FILE SUPPLIER: CHEMICAL ABSTRACTS AN=85:91566, & MATER. NAUCHNO-PRAKT. KONF. OFTAL'MOL. SEV. KAVK., 1974 USSR, pages 65-67, LAZARENKO ET AL. 'DETERMINATION OF THE VIABILITY OF THE CORNEA FOLLOWING ACUTE BURNING OF THE EYE AND THE EFFECT OF ANTIOXIDANTS ON THE COURSE OF THE BURN PROCESS' * abstract *</p> <p>---</p>	1-5	
A	<p>AUSTRALIAN AND NEW ZEALAND JOURNAL OF OPHTHALMOLOGY, vol. 15, 1987 pages 309-314, O. NEUWIRTH-LUX ET AL. 'VITAMIN E AND RABBIT CORNEAL ENDOTHELIAL CELL SURVIVAL' * the whole document *</p> <p>---</p>	1-5	
A	<p>GRAEFE'S ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, vol. 231, 1993 pages 221-227, S. SAIKA ET AL. 'ASCORBIC ACID PHOSPHATE ESTER AND WOUND HEALING IN RABBIT CORNEAL ALKALI BURNS: EPITHELIAL BASEMENT MEMBRANE AND STROMA' * the whole document *</p> <p>-----</p>	1-5	
The present search report has been drawn up for all claims			
Place of search THE HAGUE	Date of completion of the search 25 July 1995	Examiner Hoff, P	
CATEGORY OF CITED DOCUMENTS		<p>T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons</p> <p>-----</p> <p>A : member of the same patent family, corresponding document</p>	
<small>EPO FORM 1501 (02.02.92) (2001)</small>			